Compare SO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SO | SNY |
|---|---|---|
| Founded | 1946 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.1B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | SO | SNY |
|---|---|---|
| Price | $85.73 | $48.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $95.03 | $61.50 |
| AVG Volume (30 Days) | ★ 6.6M | 2.8M |
| Earning Date | 10-30-2025 | 01-29-2026 |
| Dividend Yield | ★ 3.47% | 3.32% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | 4.02 | ★ 8.67 |
| Revenue | $28,913,000,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $9.72 | $2.48 |
| Revenue Next Year | $4.77 | $6.47 |
| P/E Ratio | $21.20 | ★ $10.99 |
| Revenue Growth | ★ 9.40 | N/A |
| 52 Week Low | $80.46 | $44.62 |
| 52 Week High | $100.84 | $60.12 |
| Indicator | SO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 43.39 |
| Support Level | $83.80 | $46.97 |
| Resistance Level | $87.58 | $48.41 |
| Average True Range (ATR) | 1.44 | 0.70 |
| MACD | 0.20 | -0.09 |
| Stochastic Oscillator | 24.16 | 35.55 |
Southern is one of the largest utilities in the US. The company serves 9 million customers with vertically integrated electric utilities in three states and natural gas distribution utilities in four states. It owns 44 gigawatts of rate-regulated generating capacity, primarily for serving customers in Georgia, Alabama, and Mississippi. Subsidiary Southern Power owns 13 gigawatts of natural gas generation and renewable energy across the US and sells the electricity primarily under long-term contracts.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.